Sickle Cell Disease and Health Equity: Why This Community Has Been Left Behind and What Needs to Change
Published: 11 May 2026
Sickle cell disease is the most common inherited blood disorder in the United States. It affects approximately 100,000 Americans — predominantly Black Americans — and causes chronic pain, organ damage, and premature death. It was the first disease to be understood at the molecular level. It has been known and documented for over a century.
And for most of that century, it was systematically neglected.
The story of sickle cell disease in the United States is inseparable from the story of race in American medicine. The same disease, in a predominantly white population, would almost certainly have attracted more research funding, more treatment development, more clinical attention, and more urgent advocacy from the medical establishment.
Instead, it received comparatively little — and the consequences have been measured in the shortened lives and preventable suffering of hundreds of thousands of people.
This piece examines the health equity dimensions of sickle cell disease — the history, the current gaps, and what needs to change. It is written for advocates, healthcare professionals, researchers, and anyone committed to understanding why health equity in sickle cell disease is not a peripheral concern but a central one.
The History of Neglect
Sickle cell disease was first described in medical literature in 1910. By 1949, Linus Pauling and colleagues had identified the molecular basis of the disease — making it, as noted, the first disease understood at the molecular level. The genetic mutation responsible was identified in 1956.
Despite this early scientific attention, funding and treatment development lagged for decades. Researchers and advocates have documented the disparity in federal research funding between sickle cell disease and comparable conditions affecting predominantly white populations — most notably cystic fibrosis, which affects a similar number of Americans and has historically received significantly more NIH funding per patient.
The reasons for this disparity are not scientific. They are social and political. Sickle cell disease has predominantly affected Black Americans — a population that has been systematically marginalized in American medicine and in American society more broadly. The underfunding of sickle cell disease research is one manifestation of a broader pattern of racial inequity in healthcare.
The Nixon administration launched a national sickle cell initiative in 1972 — the first significant federal investment in the disease — but it was relatively short-lived and followed by decades of inconsistent support. It was not until the 21st century, with growing attention to health equity and the rise of patient advocacy, that research investment began to approach what the disease burden warranted.
Current Gaps in Sickle Cell Disease Care and Research
Despite recent progress, significant equity gaps persist in virtually every dimension of sickle cell disease care.
Emergency care
Studies have consistently documented that people with sickle cell disease receive slower and less adequate pain treatment in emergency departments than patients with comparable pain from other causes. The stigma surrounding sickle cell disease — and the implicit bias that contributes to skepticism about pain in Black patients — translates directly into inadequate care in acute settings.
Access to specialist care
Comprehensive sickle cell disease programs are concentrated in academic medical centers in major metropolitan areas. Patients in rural areas, in regions with smaller Black populations, or in states with limited academic medical infrastructure often have no access to specialist care. They are managed by primary care providers or general hematologists with limited sickle cell experience.
Hydroxyurea utilization
Hydroxyurea has been shown to be safe and effective for decades, and current guidelines recommend it for all children with sickle cell anemia starting at nine months. Despite this, utilization remains lower than it should be — a gap that reflects inadequate provider education, system barriers, and patient concerns that have not been adequately addressed.
Research representation
Clinical trials for sickle cell disease have historically underrepresented adults and underrepresented patients from lower-income and less-resourced communities — the very patients most affected by the disease. Research findings that do not represent the full population of people with sickle cell disease are less valid and less generalizable.
Access to new treatments
The FDA approval of two gene therapies in December 2023 represents an extraordinary scientific advance — and an extraordinary access challenge. At prices of $2.2 million and $3.1 million per patient, these therapies are inaccessible to most patients without comprehensive insurance coverage. Medicaid coverage — the payer for a significant proportion of people with sickle cell disease — is inconsistent and frequently inadequate.
Global access
The burden of sickle cell disease is primarily in sub-Saharan Africa and other low- and middle-income countries, where the vast majority of people with the disease are born. Research conducted in high-income countries and approved at high-income-country prices does nothing to address the global burden of sickle cell disease without deliberate efforts toward equitable global access.
What Medical Mistrust Means in This Context
Medical mistrust in the Black community is not irrational. It is a reasonable response to a history that includes the Tuskegee syphilis study, the unauthorized use of Henrietta Lacks’s cells, decades of inadequate pain management for Black patients, and countless documented examples of racial bias in clinical care.
That mistrust has real consequences for sickle cell disease — in clinical trial enrollment, in treatment adherence, in willingness to seek care, and in the community’s relationship with the research establishment.
Addressing medical mistrust requires more than education campaigns. It requires accountability — demonstrated changes in how institutions treat Black patients, genuine community partnership in research design, and a consistent track record of following through on commitments to equity.
Patient advocacy organizations are the primary bridge between the medical establishment and the communities most affected by sickle cell disease. Their role in rebuilding trust — where trust has been broken — is not supplementary to the research enterprise. It is foundational to it.
What Needs to Change
Research funding must reflect disease burden
Research institutions and other research funders should explicitly address the historical funding disparity in sickle cell disease relative to comparable conditions. This is not charity — it is correction of a documented inequity.
Emergency care protocols must address bias
Hospital systems should implement evidence-based pain management protocols specifically for sickle cell disease, train emergency providers in the disease, and measure and address disparities in pain treatment times and adequacy.
Access to new treatments must be a policy priority
Federal and state policymakers, insurance regulators, and Medicaid programs must develop mechanisms to ensure that the gene therapies approved in 2023 — and any future transformative treatments — are accessible to the patients who need them, not just those with the most comprehensive coverage.
Community must be at the center
Research programs, clinical initiatives, and policy advocacy in sickle cell disease must involve the community in genuine partnership — not as a recruitment target or a credibility signal, but as a co-designer and decision-maker.
Advocacy organizations need support
The patient advocacy and community-based organizations doing the most important work in the sickle cell community are often operating with minimal resources. Investing in their capacity — through funding, partnerships, and infrastructure — is one of the most effective ways to advance sickle cell disease outcomes.
The Role of Elevate Impact
Elevate Impact was built, in part, as a direct response to the equity gaps in sickle cell disease.
We chose to start with sickle cell disease because the community is underserved, the advocacy ecosystem is strong but under-resourced, and the need for structured cross-sector collaboration is urgent. We believe that building the infrastructure for authentic partnership between advocacy organizations, clinicians, researchers, and industry is one of the most important things we can do to advance health equity in this space.
Our platform, our toolkit, and our community are specifically designed to support the organizations doing this work — by connecting them to partners, providing frameworks for accountable collaboration, and building the community infrastructure that makes sustained advocacy possible.
Frequently Asked Questions
Sickle cell disease disproportionately affects Black Americans and has been chronically underfunded relative to conditions affecting predominantly white populations with similar or smaller patient populations. This disparity in research investment, clinical attention, and treatment development is a direct consequence of racial inequity in American medicine and society.
Researchers and advocates have documented that sickle cell disease has historically received less funding per patient than comparable conditions like cystic fibrosis. This gap has narrowed in recent years as health equity has received more attention, but the cumulative effects of decades of underfunding continue to affect the field.
Medical mistrust in the Black community — rooted in a documented history of harmful and unethical medical practices — affects sickle cell disease in multiple ways: lower clinical trial enrollment, reduced treatment adherence, delayed care-seeking, and the community’s relationship with the research establishment. Addressing it requires demonstrated accountability and authentic community partnership, not just education campaigns.
The gene therapies approved in December 2023 are priced at $2.2 million and $3.1 million per patient. Insurance coverage — particularly through Medicaid, which covers a significant proportion of sickle cell patients — is inconsistent. Treatment requires specialized centers that are not available in all geographies. And the conditioning chemotherapy required for these therapies carries significant risks that affect eligibility and willingness to pursue treatment.
Key actions include implementing evidence-based pain management protocols for sickle cell disease in emergency departments, training providers in the disease, measuring and addressing racial disparities in care, developing formal community partnership programs with advocacy organizations, and advocating for equitable access to new treatments.
Elevate Impact’s platform and community are specifically designed to support the advocacy organizations, clinicians, and researchers working to advance health equity in sickle cell disease — providing the infrastructure for authentic cross-sector collaboration, the tools for impact measurement and accountability, and the community connections that make sustained advocacy possible.
The health equity gaps in sickle cell disease are not accidents. They are the product of specific historical decisions — about research funding, about clinical training, about whose suffering is treated as urgent — that reflect deeper patterns of racial inequity in American medicine.
Changing them requires acknowledgment, accountability, and action — from research funders, from hospital systems, from policymakers, from industry, and from the broader healthcare community.
The sickle cell advocacy community has been doing this work for decades with insufficient support. It is time for that to change.
Elevate Impact is committed to being part of that change.
